Revolutionizing Cancer Care: MediLink Therapeutics Pioneers Breakthrough ADC Research for Game-Changing Cancer Treatments

Unlocking Hope: YL201 Phase I/II Oncology Summit Sparks Excitement in Guangzhou

GUANGZHOU, China, Sept. 23, 2023 /PRNewswire/ — In a momentous gathering on September 23, 2023, luminaries in the field of oncology representing over 60 clinical research centers from across China convened in Guangzhou. Their mission: to participate in the eagerly anticipated YL201 Phase I/II Investigators Meeting, graciously hosted by Suzhou MediLink Therapeutics Co., Ltd.

Steering this symposium of brilliance was none other than Professor Li Zhang, a luminary hailing from the prestigious Cancer Center of Sun Yat-sen University. Together, these experts delved deep into the development strategy of the clinical trial protocol, forging a rock-solid path toward the efficient drug development of YL201.

The chairperson of this momentous assembly, Lead Investigator Professor Li Zhang, took the stage to proclaim, “ADC research is currently the beacon of hope in cancer treatment, and the international multi-center clinical trial data from MediLink’s YL201 project has ignited excitement. The prospect of a groundbreaking therapy is on the horizon, setting the stage for swift advancement into Phase I/II. Here’s to further progress and new horizons in cancer treatment.”

During the meeting, Professor Hongyun Zhao unveiled thrilling clinical trial data from the recent successful dose exploration phase, sending ripples of enthusiasm through the audience.

Dr. Tongtong Xue, the Chairman and CEO of MediLink Therapeutics, kicked off the event with a flourish, declaring, “We are truly honored to gather oncology experts from across China to witness the remarkable journey of MediLink. In just 1.5 years, our dynamic team, researchers, and collaborators have affirmed YL201’s safety.

Today’s meeting marks the first fruits of our proprietary TAMLIN antibody conjugation technology. Yet, we know there’s a long road ahead. MediLink remains committed to accelerating YL201’s development, pushing the boundaries of cancer treatment, and bringing hope to countless patients.”

About MediLink Therapeutics:

Founded in 2020, MediLink Therapeutics is no ordinary biopharmaceutical company. We are a beacon of hope in the field of cancer treatment, dedicated to crafting innovative Antibody Drug Conjugates (ADC). Armed with our proprietary Tumor Microenvironment Activable LINker-payload (TMALIN®) technology, we’re not just raising the bar; we’re setting new standards in ADC development. Our goal? To offer more potent and effective treatment options to cancer patients worldwide.

Based in Suzhou, China, with R&D hubs in Shanghai, Boston, and the USA, we’re breaking boundaries and shaping the future of cancer therapy.

Leave a Comment